Dyne and Sarepta shares slump as Novartis trial setback hits muscle disease stocks

Shares of Dyne Therapeutics (DYN) and Sarepta (SRPT) fell Tuesday after Novartis’ NOT treatment for a muscle-wasting disorder failed in a trial, raising concerns about similar therapies for a rare disease.